Avoro Capital Advisors Reduces Its Stake in RNAM ($RNAM)
Avoro Capital Advisors sold its entire stake in RNAM, totaling 5.46 million shares.
Key Points
- Avoro Capital Advisors sold its entire position in RNAM, eliminating 5.46 million shares in its latest 13F filing.
- RNAM has seen insider selling with key executives, including the CEO and Chief Legal Officer, offloading shares on February 27, 2026.
- Other institutional investors like CORSICANA & CO. added 8,000 shares, while several others exited their positions entirely.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors has completely sold out its position in RNAM, according to its latest 13F filing with the SEC. The fund cut 5.46 million shares, bringing its holdings to zero. This move was reported as of the filing date, May 15, 2026.
What Changed in Avoro Capital Advisors's RNAM Position
Avoro Capital Advisors eliminated its entire stake in RNAM, which previously stood at 5.46 million shares. This reduction represents a 100% decrease in its holdings, as the fund no longer holds any shares in the company.
Other Institutional Activity in RNAM
Other institutional investors have also adjusted their positions in RNAM. CORSICANA & CO. increased its holdings by 8,000 shares, ending with 8,000 shares valued at approximately $236,160. In contrast, Z3 CAPITAL PARTNERS, LLC, ROCKEFELLER CAPITAL MANAGEMENT L.P., and TD CAPITAL MANAGEMENT LLC all exited their positions completely, each reducing their holdings to zero. BLUEFIN CAPITAL MANAGEMENT, LLC also sold out its stake, cutting 10,000 shares.
Insider Buying and Selling at RNAM
Insider activity at RNAM has been notable. On February 27, 2026, several key executives sold shares. Chief Scientific Officer Michael Flanagan sold 397,500 shares, while President and CEO Sarah Boyce offloaded 474,861 shares. Other insiders, including Chief Legal Officer John Moriarty and Edward Kaye, MD, also sold significant numbers of shares.
Bottom Line
Avoro Capital Advisors's decision to sell its entire stake in RNAM is a significant move that investors will watch closely. This 13F filing, while backward-looking, provides insight into the fund's past investment strategy. As always, these filings reflect only the holdings at the end of the reporting period and do not necessarily indicate current positions.
Get RNAM alerts
New 13F filings, insider trades, and analyst moves on $RNAM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.